MURAL ONCOLOGY Trademark

Trademark Overview


On Wednesday, April 26, 2023, a trademark application was filed for MURAL ONCOLOGY with the United States Patent and Trademark Office. The USPTO has given the MURAL ONCOLOGY trademark a serial number of 97907947. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Monday, October 28, 2024. This trademark is owned by Alkermes Pharma Ireland Limited. The MURAL ONCOLOGY trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical prep...

Therapeutic proteins for use in the manufacture of pharmaceutical preparations

Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment

Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data...
mural oncology

General Information


Serial Number97907947
Word MarkMURAL ONCOLOGY
Filing DateWednesday, April 26, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateMonday, October 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesBiopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer
Goods and ServicesTherapeutic proteins for use in the manufacture of pharmaceutical preparations
Goods and ServicesProviding educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment
NOT AVAILABLE"ONCOLOGY"
Goods and ServicesResearch and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, September 12, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 24, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 24, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 24, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMURAL ONCOLOGY, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressWALTHAM, MA 02451

Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin 4
IE

Trademark Events


Event DateEvent Description
Monday, May 1, 2023NEW APPLICATION ENTERED
Wednesday, May 24, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 23, 2024ASSIGNED TO EXAMINER
Thursday, January 25, 2024NON-FINAL ACTION WRITTEN
Thursday, January 25, 2024NON-FINAL ACTION E-MAILED
Thursday, January 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 28, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, September 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 12, 2024ASSIGNED TO LIE
Monday, October 28, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, October 28, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, October 28, 2024EXAMINER'S AMENDMENT ENTERED
Monday, October 28, 2024EXAMINERS AMENDMENT -WRITTEN
Monday, October 28, 2024EXAMINERS AMENDMENT E-MAILED
Monday, October 28, 2024SUSPENSION LETTER WRITTEN
Monday, October 28, 2024LETTER OF SUSPENSION E-MAILED
Thursday, September 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE